Cannabinoids for the treatment of neuropathic pain: clinical evidence
- PMID:18183533
Cannabinoids for the treatment of neuropathic pain: clinical evidence
Abstract
Neuropathic pain is a worldwide epidemic that occurs in 3 to 8% of individuals in industrialized countries and is often refractory to existing treatments. Drugs currently available to target neuropathic pain are, at best, moderately effective and include antidepressants, gabapentin, NMDA receptor antagonists, as well as other anticonvulsants, all of which are limited by their adverse-effect profiles. Cannabinoid drugs are emerging as a promising class of drugs to treat neuropathic pain and have been tested for analgesic effects in a range of chronic pain conditions. Data show that cannabinoids are often effective in individuals with refractory pain receiving concomitant analgesic drugs. Clinical studies on cannabinoids for the treatment of neuropathic pain are reviewed, focusing on clinical trials published within the last five years. Data from large, well-controlled studies show that cannabinoids are moderately effective in reducing chronic pain and that side effects are comparable to existing treatments, suggesting that cannabinoids can play a useful role in the management of chronic pain. Like other drugs for neuropathic pain, cannabinoids have a dose titration that is limited by psychoactive side effects. The development of cannabinoid drugs to target neuropathic pain with improved therapeutic ratios will depend upon the development of cannabinoid treatments with reduced psychoactivity.
Similar articles
- Management of neuropathic pain.Jensen TS, Finnerup NB.Jensen TS, et al.Curr Opin Support Palliat Care. 2007 Aug;1(2):126-31. doi: 10.1097/SPC.0b013e3282eeb45f.Curr Opin Support Palliat Care. 2007.PMID:18685353Review.
- Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.Pergolizzi J, et al.Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.Pain Pract. 2008.PMID:18503626
- Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.Rice AS, Farquhar-Smith WP, Nagy I.Rice AS, et al.Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):243-56. doi: 10.1054/plef.2001.0362.Prostaglandins Leukot Essent Fatty Acids. 2002.PMID:12052040Review.
- Reassessment of the role of cannabinoids in the management of pain.Beaulieu P, Ware M.Beaulieu P, et al.Curr Opin Anaesthesiol. 2007 Oct;20(5):473-7. doi: 10.1097/ACO.0b013e3282efd175.Curr Opin Anaesthesiol. 2007.PMID:17873600Review.
- [Use of cannabinoids in palliative medicine].Ernst G, Kongsgaard UE.Ernst G, et al.Tidsskr Nor Laegeforen. 2008 Apr 3;128(7):822-5.Tidsskr Nor Laegeforen. 2008.PMID:18389029Review.Norwegian.
Cited by
- Cannabinoids and an anti-inflammatory diet for the treatment of neuropathic pain after spinal cord injury (The CATNP Study): study protocol for a randomized controlled trial.Allison DJ, Agudelo AR, Chan BCF, Ditor DS, Loh E.Allison DJ, et al.Spinal Cord. 2021 Feb;59(2):112-122. doi: 10.1038/s41393-020-0508-5. Epub 2020 Jul 1.Spinal Cord. 2021.PMID:32612213
- Translational pain research: achievements and challenges.Mao J.Mao J.J Pain. 2009 Oct;10(10):1001-11. doi: 10.1016/j.jpain.2009.06.002. Epub 2009 Jul 22.J Pain. 2009.PMID:19628433Free PMC article.Review.
- Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate.Sánchez-Blázquez P, Rodríguez-Muñoz M, Vicente-Sánchez A, Garzón J.Sánchez-Blázquez P, et al.Antioxid Redox Signal. 2013 Nov 20;19(15):1766-82. doi: 10.1089/ars.2012.5100. Epub 2013 Jun 1.Antioxid Redox Signal. 2013.PMID:23600761Free PMC article.
- Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS.Andreae MH, et al.J Pain. 2015 Dec;16(12):1221-1232. doi: 10.1016/j.jpain.2015.07.009. Epub 2015 Sep 9.J Pain. 2015.PMID:26362106Free PMC article.Review.
- The CB2 Agonist β-Caryophyllene in Male and Female Rats Exposed to a Model of Persistent Inflammatory Pain.Ceccarelli I, Fiorenzani P, Pessina F, Pinassi J, Aglianò M, Miragliotta V, Aloisi AM.Ceccarelli I, et al.Front Neurosci. 2020 Aug 18;14:850. doi: 10.3389/fnins.2020.00850. eCollection 2020.Front Neurosci. 2020.PMID:33013287Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical